All News
Pearls on Rheum imaging:
👉CPPD is not erosive
👉SC joint in OA is common (hard to image)
👉AC joint is 1st place OA affects shoulders (not GH)
👉Neuropathic OA progress rapidly, look at the TMTs
👉Get more views if you aren't seeing what you need
#ACR21 Radiology Bootcamp
TheDaoIndex KDAO2011 ( View Tweet)
Another one from Dallas! Congrats, Dr. Limanni! #ACR21 https://t.co/Rs3muuFQKh
TheDaoIndex KDAO2011 ( View Tweet)
Dr Oster presenting on IL-23 inhibitor Risankizumab in PsA. No surprises here, it works. We need comparative efficacy trials! Abstr#0453 #ACR21 @RheumNow https://t.co/mj8TeCqEcg
Richard Conway RichardPAConway ( View Tweet)
Plenary I
0454 LN mortality in the US & disparities using CDC WONDER data 1999-2019
"LN mortality exhibited profound disparities by race/ethnicity and place of residence"
https://t.co/UtMzaiL14D
#ACR21 https://t.co/C3fuq8anvR
Rheum Cat rheum_cat ( View Tweet)
#ClinicalPearl What lasts longer/⬆️retention in sero+ RA: Abatacept or TNFi or JAKi? #ACR21 abst#0463 @RheumNow Adjusting for confounding incl line of Rx / past bio Rx, #abatacept wins. But data not stratified for bio naive or exposed. Not sure if that would alter results https://t.co/1dEQncwPQF
Janet Pope Janetbirdope ( View Tweet)
The best overall winner for the #ACR21 image competition https://t.co/Kr9EVAYVip
Rheum Cat rheum_cat ( View Tweet)
#ACR21 #ACR2021 #ACRLive
wonderful slide set to explain the spinal phytes https://t.co/5SxN7GeDzh
EnvisionRheumat ERheumat ( View Tweet)
#ACR21 Convergence Begins! Tune into our latest podcast where Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.
https://t.co/UnFiUR91vB https://t.co/NxVzeQbP4H
Links:
Dr. John Cush RheumNow ( View Tweet)
Factors that predict trajectories of radiographic progression in #axialspondyloarthritis 4 major patterns in the PSOAS cohort. Male gender, longer disease duration, raised CRP and smoking associated with higher spinal progression @RheumNow #ACR21 Abst#450 https://t.co/PvDE7T0MZp
Dr. Antoni Chan synovialjoints ( View Tweet)
Abst 0450 #ACR21 @RheumNow PSOAS cohort 4 trajectories of radiographic progression in AS: Non-progressors 37%, late-progressors 26%, early-progressors 19%, rapid-progressors 18%.⬆️ disease burden: male, longer disease duration & smoking . ⬆️eCRP=higher disease progression https://t.co/wUdBNzJPy0
Olga Petryna DrPetryna ( View Tweet)
Abst 0452 #ACR21 #acrbest @RheumNow TB-PET/CT in PsA helps differentiate from RA/OA &measure inflammatory burden. Main findings asymmetric synovitis,systemic enthesitis, DIP& extensor tendons inflammation& adjacent nail matrix inflammation, Sacroiliitis& diffuse spine enthesitis https://t.co/7nTSIbmKfE
Olga Petryna DrPetryna ( View Tweet)
ASRI data: high frequency of pregnancy and fetal complications (miscarriage, c-section, early delivery, NICU admission) in AxSpA pts. We need more studies regarding risks/tx/outcomes/breastfeeding guidance. Abs 0369 #ACR21 #RheumNow @RheumNow https://t.co/4BR2ZPPjyB https://t.co/qyTwtfEMMy
Dr. Rachel Tate uptoTate ( View Tweet)
#ClinicalPearl Leflunomide for chronic CMV retinitis failing antiviral Rx? Suppresses inflammation & Arava May have antiviral properties. Didn’t know it. Kolfenbach & Palestine 6S117 eye opening experiences #ACR21 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
What increases risk of RA-assoc #bronchiectasis, separate from #RA-ILD?
Results from @BrighamResearch find seropositivity (esp high +ve RF/CCP), older age, disease duration, & low BMI incr. risk of isolated bronchiectasis in RA.
#ACR21 Abs#0288 @RheumNow
https://t.co/jvvRucqTjL https://t.co/aFCfxrbUdV
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. Petri et al showed transition between lupus anticoagulant (-) to (+), (+) to (-), and (+) or (-) to thrombosis could be estimated by multistate Markov model.
#ACR21 Abst#0076 @RheumNow https://t.co/oIvbak4lV4
Pedro Castillo _Castillo_Pedro ( View Tweet)
Retrospective study of FAERS database: 186 irAE w/rheum manifestation
👉4.7% of all AEs
👉Arthritis, myositis, Sjogren, sarcoidosis were frequent
👉myositis assc w/ durvalumab, avelumab, atezolimumab and cemiplimab
#ACR21 Abstr#0438 #Plenary @rheumnow https://t.co/t8UQWQicFc https://t.co/FGo6WCDQTp
TheDaoIndex KDAO2011 ( View Tweet)
@BethIWallace et al. on fibromyalgianess and GC in #rheumatoidarthritis pts.
Accdg to their study, pts w/⬆ levels of fibromyalgianess at BL had higher odds of GC persistence on ffup.
Something to consider when evaluating need for GC adjustment.
@RheumNow #ACR21 abs0120 https://t.co/MTWEXGHJ2n
sheila RHEUMarampa ( View Tweet)
Retrospective study of cancer pts Rx w/ ICI and autoimmune Ab (ANA, RF, CCP, SSA/SSB, ANCA)
👉152 pts
👉59% had irAE
👉preICI Ab+⬆️odds of irAE (OR 17.5 95% CI 1.76-174, p=0.015)
👉strong assc b/t +RF and +CCP for ICD-arthritis
#ACR21 Abst#0440 @Rheumnow https://t.co/kUv5ddSAnY
TheDaoIndex KDAO2011 ( View Tweet)
Large case-control study (n=8028) to identify baseline predictors of rheum irAEs after immune checkpoint inhibitor initiation for cancer.
Type of cancer (melanoma, GU), combination ICI, pre-existing autoimmune disease, and recent GC use each had higher odds of rheum irAE #ACR21 https://t.co/rHI6VQ37QB
Jeffrey Sparks MD MMSc jeffsparks ( View Tweet)
#ClinicalPearl Joint clinic btwn ophthalmology & #rheumatology helps make dx & Rx work. #ACRBest #ACR21 see work up of inflammatory eyes disease. All are allowed one acute ant uveitis- ? dogma maybe work up all. 6S117 https://t.co/Wwdv3N66HS
Janet Pope Janetbirdope ( View Tweet)